Ning 2014.
Methods | Multicentre, double‐blind, placebo‐controlled trial |
Participants | Participants with type 2 diabetes inadequately controlled (HbA1c 7.5%‐11.0%) on stable therapy with long‐acting, intermediate‐acting or premixed insulin, with or without concomitant metformin |
Interventions | Vildagliptin 50 mg twice a day (n = 146) or placebo (n = 147) |
Outcomes | HbA1c, fasting blood glucose, BMI |
Notes | Need to determine if subgroup analysis with insulin monotherapy is possible |